Platinum sponsor NantHealth will showcase GPS Cancer® and precision medicine solutions for oncology at booth #314

Culver City, California and Washington D.C. March 14, 2018 NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today that they will be exhibiting at the Association of Community Cancer Centers (ACCC) 44th Annual Meeting & Cancer Center Business Summit taking place March 14-16 at the Renaissance Washington, DC Downtown Hotel at booth #314. As a platinum level sponsor of the summit, NantHealth is proud to support this powerful community of multidisciplinary practitioners in their efforts to promote the highest quality of cancer care.

NantHealth scientific and clinical experts will be onsite to discuss recent data on the importance of tumor-normal sequencing to deliver precise information to oncologists to inform their treatment decisions for patients. NantHealth’s GPS Cancer solution provides the most comprehensive molecular profile available to inform personalized treatment strategies – from DNA to RNA to protein. By analyzing a patient’s individual tumor profile, GPS Cancer offers insight into therapies that may have potential benefits, including FDA approved therapies and active clinical trials, and therapies to which the cancer may be resistant.

“As value-based care increases in importance and becomes further embedded into healthcare practices, precision medicine will play a critical role in effectively managing the health of not only the population, but individuals,” said Patrick Soon-Shiong, MD, founder and CEO of NantHealth. “By putting patients at the center of their own care, precision medicine has the capacity to generate robust information about their individual and unique rare diseases and enable researchers to develop more effective therapies for superior treatment.”

Unlike other tests on the market, GPS Cancer sequences the whole genome of 20,000+ genes and three billion base pairs and matches against the patient’s normal DNA, providing oncologists with a precise view of alterations to inform personalized treatment strategies. This clinically relevant information helps oncologists to better understand how patients may potentially respond to chemotherapies, targeted therapies and immunotherapies. GPS Cancer is performed in CAP-accredited, CLIA-certified labs.

As a platinum sponsor of this event, NantHealth is committed to empowering every member of the multidisciplinary cancer team to provide exceptional patient care. By leveraging the latest advancements in precision medicine and software technology to enable true value-based care, NantHealth believes that a successful transition to next generation healthcare solutions is possible for every organization.

Visit NantHealth at booth #314 to learn more about GPS Cancer and how our holistic and comprehensive solutions are transforming the way illness is known and treated. To schedule a private meeting with a sales, product, or marketing representative please enter your information here.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s focused portfolio exemplifies its unique systems-based approach to personalized healthcare and integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine.  For more information please visit

About GPS Cancer®

GPS Cancer® is a unique, molecular scan available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer and an assessment of protein pathway function to inform personalized treatment strategies. GPS Cancer scanning is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit

Press Contact:
Jen Hodson